Multiple Authorship

In response to Murray Saffran’s.article entitled “On Multiple Authorship: Describe The Contribution” (The Scientist, March 20, 1989, page 9), I would like to suggest and appeal to the editors of scientific journals as well as to the NIH and the NSF to make a rule that would apply to both authorship and grant proposals: “Any individual who has been a coauthor on any paper (except that from a multicenter clinical trial) with a principal investigator (author) and co-invest

Written bySushil Jan
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

In response to Murray Saffran’s.article entitled “On Multiple Authorship: Describe The Contribution” (The Scientist, March 20, 1989, page 9), I would like to suggest and appeal to the editors of scientific journals as well as to the NIH and the NSF to make a rule that would apply to both authorship and grant proposals: “Any individual who has been a coauthor on any paper (except that from a multicenter clinical trial) with a principal investigator (author) and co-investigator (co-author) of the grant or manuscript under review, should not review or participate in discussions on that particular grant funding or manuscript publication.”

This will remove not only grants authorships on a large number of manuscripts but will also make the NIH and NSF grant funding fairer.

SUSHIL K. JAN
School of Medicine
LouisianaState University
Medical Center
Shreveport, La.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies